AR052266A1 - Derivados de pirroles, su preparacion, y su uso como compuestos farmaceuticos - Google Patents
Derivados de pirroles, su preparacion, y su uso como compuestos farmaceuticosInfo
- Publication number
- AR052266A1 AR052266A1 ARP050105197A ARP050105197A AR052266A1 AR 052266 A1 AR052266 A1 AR 052266A1 AR P050105197 A ARP050105197 A AR P050105197A AR P050105197 A ARP050105197 A AR P050105197A AR 052266 A1 AR052266 A1 AR 052266A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- amino
- group
- atoms
- membered heterocyclic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Otolaryngology (AREA)
Abstract
Un proceso para prepararlos, y su uso como productos farmacéuticos. Reivindicacion 1: Un compuesto de la formula (1) en forma libre o de sal farmacéuticamente aceptable, en donde Q es [cR1R2]m; R1 y R2 son independientemente H, alquilo C1-8, o junto con el átomo de C con el que están unidos, forman un grupo cicloalifático divalente de 3 a 8 átomos de C; R3 y R4 se seleccionan independientemente a partir de H y alquilo C1-8; R5 se selecciona a partir de H, halogeno, alquilo C1-8, haloalquilo C1-8, un grupo carbocíclico de 3 a 15 átomos de C, nitro, ciano, SO2R5a, SOR5b, SR5c, alquilo C1-8-carbonilo, alcoxilo C1-8-carbonilo, alcoxilo C1-8, haloalcoxilo C1-8, carboxilo, carboxi-alquilo C1-8, amino, amino-(alquilo C1-8), alquilo C1-8-amino, di-(alquilo C1-8)-amino, SO2NR5dR5e, -C(O)NR5fR5g, un grupo carbocíclico aromático de 6 a 15 átomos de C, y un grupo heterocíclico de 4 a 10 miembros que tiene uno o más heteroátomos seleccionados a partir del grupo que consiste en O, N y S; R5a, R5b y R5c se seleccionan independientemente a partir de alquilo C1-8, hidroxialquilo C1-8, alquilo C1-8-amino-(alquilo C1-8), di-(alquilo C1-8)- amino-(alquilo C1-8), cianoalquilo C1-8, un grupo carbocíclico de 3 a 15 átomos de C, haloalquilo C1-8, y un grupo heterocíclico de 4 a 10 miembros que tiene uno o más heteroátomos seleccionados a partir del grupo que consiste en O, N, y S; R5d, R5e, R5f, y R5g son independientemente H, alquilo C1-8, hidroxialquilo C1-8, alquilo C1-8- amino-(alquilo C1-8), di-(alquilo C1-8)-amino-(alquilo C1-8), cianoalquilo C1-8, un grupo carbocíclico de 3 a 15 átomos de C, haloalquilo C1-8, y un grupo heterocíclico de 4 a 10 miembros que tiene uno o más heteroátomos seleccionados a partir del grupo que consiste en O, N, y S; o junto con el átomo de N con el que están unidos, forman un grupo heterocíclico de 4 a 10 átomos de C; R6 se selecciona a partir de H, halogeno, alquilo C1-8, haloalquilo C1-8, un grupo carbocíclico de 3 a 15 átomos de C, nitro, ciano, SO2R6a, alquilo C1-8-carbonilo, alcoxilo C1-8-carbonilo, alcoxilo C1-8, haloalcoxilo C1-8, -SR6b, carboxilo, carboxi-alquilo C1-8, amino, amino-(alquilo C1-8), alquilo C18-amino-(alquilo C1-8), di-(alquilo C1-8)-amino-(alquilo C1- 8), alquilo C1-8-amino, di-(alquilo C1-8)-amino, SO2NR6cR6d, -C(O)NR6eR6f, hidroxialquilo C1-8, NR6gSO2R6h, NR6i(CO)R6j, SOR6k, un grupo carbocíclico aromático de 6 a 15 átomos de C, y un grupo heterocíclico de 4 a 10 miembros que tiene uno o más heteroátomos seleccionados a partir del grupo que consiste en O, N y S; R6a, R6k, y R6b se seleccionan independientemente a partir de alquilo C1-8, hidroxialquilo C1-8, alquilo C1-8-amino-(alquilo C1-8), di-(alquilo C1-8)-amino-(alquilo C1-8), cianoalquilo C1-8, un grupo carbocíclico de 3 a 15 átomos de C, haloalquilo C1-8, y un grupo heterocíclico de 4 a 10 miembros que tiene uno o más heteroátomos seleccionados a partir del grupo que consiste en O, N y S; R6c, R6d,R6e, y R6f son independientemente H, alquilo C1-8, hidroxialquilo C1-8, alquilo C1-8-amino-(alquilo C1-8), di-(alquilo C1-8)-amino-(alquilo C1-8), cianoalquilo C1-8, un grupo carbocíclico de 3 a 15 átomos de C, haloalquilo C1-8, un grupo heterocíclico de 4 a 10 miembros que tiene uno o más heteroátomos seleccionados a partir del grupo que consiste en O, N, y S, o junto con el átomo de N con el que están unidos, forman un grupo heterocíclico de 4 a 10 átomos de C; R6g y R6i se seleccionan independientemente a partir de H, alquilo C1-8, hidroxialquilo C1-8, alquilo C1-8-amino-(alquilo C1-8), di-(alquilo C1-8)-amino-(alquilo C1-8), cianoalquilo C1-8, un grupo carbocíclico de 3 a 15 átomos de C, haloalquilo C1-8, y un grupo heterocíclico de 4 a 10 miembros que tiene uno o más heteroátomos seleccionados a partir del grupo que consiste en O, N, y S; R6h y R6j se seleccionan independientemente a partir de alquilo C1-8, un grupo carbocíclico de 3 a 15 átomos de C, un grupo heterocíclico de 4 a 10 miembros que tiene uno o más heteroátomos seleccionados a partir del grupo que consiste en O, N y S, hidroxialquilo C1-8, amino-(alquilo C1-8), alquilo C1-8-amino-(alquilo C1-8), di-(alquilo C1-8)-amino-(alquilo C1-8), y cianoalquilo C1-8;W se selecciona a partir de un grupo carbocíclico de 3 a 15 átomos de C, y un heterociclo de 4 a 10 miembros que tiene uno o más heteroátomos seleccionados a partir del grupo que consiste en O, N y S; m es un entero seleccionado a partir de 1 a 3; y n es un entero seleccionado a partir de 1 a 4.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0427381.9A GB0427381D0 (en) | 2004-12-14 | 2004-12-14 | Organic compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
AR052266A1 true AR052266A1 (es) | 2007-03-07 |
Family
ID=34090028
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP050105197A AR052266A1 (es) | 2004-12-14 | 2005-12-12 | Derivados de pirroles, su preparacion, y su uso como compuestos farmaceuticos |
Country Status (21)
Country | Link |
---|---|
US (1) | US20100087432A1 (es) |
EP (1) | EP1828172B1 (es) |
JP (1) | JP2008523130A (es) |
KR (1) | KR20070087605A (es) |
CN (1) | CN101072773B (es) |
AR (1) | AR052266A1 (es) |
AT (1) | ATE449772T1 (es) |
AU (1) | AU2005315881C1 (es) |
BR (1) | BRPI0518607A2 (es) |
CA (1) | CA2587934A1 (es) |
DE (1) | DE602005017935D1 (es) |
ES (1) | ES2335519T3 (es) |
GB (1) | GB0427381D0 (es) |
GT (1) | GT200500360A (es) |
MX (1) | MX2007007098A (es) |
PE (1) | PE20060736A1 (es) |
PL (1) | PL1828172T3 (es) |
PT (1) | PT1828172E (es) |
RU (1) | RU2007126761A (es) |
TW (1) | TW200635921A (es) |
WO (1) | WO2006063763A1 (es) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0611695D0 (en) * | 2006-06-13 | 2006-07-26 | Novartis Ag | Organic compounds |
TW200848019A (en) * | 2007-03-06 | 2008-12-16 | Wyeth Corp | Aryl sulfonamides useful for modulation of the progesterone receptor |
PT2229358E (pt) | 2007-12-14 | 2011-06-29 | Pulmagen Therapeutics Asthma Ltd | Indoles e sua utilização terapêutica |
MA33134B1 (fr) * | 2009-02-24 | 2012-03-01 | Merck Canada Inc | Derives d'indole en tant qu'antagonistes du recepteur crth2 |
CA2785191A1 (en) | 2009-12-23 | 2011-06-30 | Ironwood Pharmaceuticals, Inc. | Crth2 modulators |
SI2558447T1 (sl) | 2010-03-22 | 2015-01-30 | Actelion Pharmaceuticals Ltd. | Derivati 3-(heteroaril-amino)-1,2,3,4-tetrahidro-9h-karbazola in njihova uporaba kot modulatorji prostaglandinskega receptorja d2 |
WO2011117184A1 (de) | 2010-03-24 | 2011-09-29 | Bayer Cropscience Ag | Fludioxonil-derivate |
EP2457900A1 (en) | 2010-11-25 | 2012-05-30 | Almirall, S.A. | New pyrazole derivatives having CRTh2 antagonistic behaviour |
WO2012078210A1 (en) * | 2010-12-08 | 2012-06-14 | Ironwood Pharmaceuticals, Inc. | Crth2 modulators and preparation thereof |
PT2697223T (pt) | 2011-04-14 | 2016-10-14 | Actelion Pharmaceuticals Ltd | Derivados de ácido 7-(heteroaril-amino)-6,7,8,9-tetraidropirido[1,2-a]indolacético e utilização dos mesmos como moduladores do recetor d2 de prostaglandina |
CN104114169A (zh) | 2011-12-16 | 2014-10-22 | 阿托佩斯治疗有限公司 | 用于治疗嗜酸细胞性食管炎的crth2拮抗剂和质子泵抑制剂的组合物 |
WO2013093842A1 (en) | 2011-12-21 | 2013-06-27 | Actelion Pharmaceuticals Ltd | Heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators |
WO2013155422A1 (en) * | 2012-04-12 | 2013-10-17 | Ironwood Pharmaceuticals, Inc. | Methods of treating alopecia and acne |
CA2876808A1 (en) | 2012-07-05 | 2014-01-09 | Actelion Pharmaceuticals Ltd | 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators |
ES2461415B1 (es) * | 2012-10-16 | 2015-03-16 | Consejo Superior De Investigaciones Científicas (Csic) | Derivados funcionalizados e inmunorreactivos para el fungicida fludioxonil |
CN103553991B (zh) * | 2013-11-08 | 2016-01-20 | 苏州诚和医药化学有限公司 | 一种制备2-甲氧基-4-氨基-5-乙砜基苯甲酸甲酯的方法 |
CN103553990B (zh) * | 2013-11-08 | 2016-01-20 | 苏州诚和医药化学有限公司 | 用卤素卤化合成2-甲氧基-4-氨基-5-乙砜基苯甲酸甲酯的方法 |
CN103588686B (zh) * | 2013-11-08 | 2016-01-20 | 苏州诚和医药化学有限公司 | 一种用卤素卤化制备2-甲氧基-4-氨基-5-乙砜基苯甲酸甲酯的方法 |
CN106103435B (zh) | 2014-03-17 | 2018-11-16 | 爱杜西亚药品有限公司 | 氮杂吲哚乙酸衍生物及彼等作为前列腺素d2受体调节剂的用途 |
WO2015140701A1 (en) | 2014-03-18 | 2015-09-24 | Actelion Pharmaceuticals Ltd | Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators |
CN108026093B (zh) | 2015-09-15 | 2021-11-16 | 爱杜西亚药品有限公司 | 结晶形式 |
CN108164502B (zh) * | 2018-03-06 | 2021-04-13 | 苏州华一新能源科技有限公司 | 1,3-丙烷磺酸内酯的制备方法 |
CN112602714B (zh) * | 2020-12-23 | 2021-11-16 | 华南农业大学 | 一类咯菌腈羧酸衍生物在用于植物维管组织靶向药剂中的应用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0182737A3 (de) * | 1984-10-16 | 1986-10-08 | Ciba-Geigy Ag | 3-Phenylpyrrolderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel |
EP0386681A1 (de) * | 1989-03-08 | 1990-09-12 | Ciba-Geigy Ag | 3-Aryl-4-cyano-pyrrol-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende mikrobiozide Mittel |
AU2002367424A1 (en) * | 2001-12-28 | 2003-07-24 | Takeda Chemical Industries, Ltd. | Androgen receptor antagonists |
JP4316232B2 (ja) * | 2001-12-28 | 2009-08-19 | 武田薬品工業株式会社 | アンドロゲン受容体拮抗剤 |
TW200307542A (en) * | 2002-05-30 | 2003-12-16 | Astrazeneca Ab | Novel compounds |
SE0301010D0 (sv) * | 2003-04-07 | 2003-04-07 | Astrazeneca Ab | Novel compounds |
GB0308466D0 (en) * | 2003-04-11 | 2003-05-21 | Novartis Ag | Organic compounds |
US20080119456A1 (en) * | 2004-05-29 | 2008-05-22 | Trond Ulven | Substituted Thiazoleacetic Acid as Crth2 Ligands |
-
2004
- 2004-12-14 GB GBGB0427381.9A patent/GB0427381D0/en not_active Ceased
-
2005
- 2005-12-07 GT GT200500360A patent/GT200500360A/es unknown
- 2005-12-12 AR ARP050105197A patent/AR052266A1/es not_active Application Discontinuation
- 2005-12-12 RU RU2007126761/04A patent/RU2007126761A/ru not_active Application Discontinuation
- 2005-12-12 CA CA002587934A patent/CA2587934A1/en not_active Abandoned
- 2005-12-12 AT AT05815747T patent/ATE449772T1/de not_active IP Right Cessation
- 2005-12-12 KR KR1020077013302A patent/KR20070087605A/ko active IP Right Grant
- 2005-12-12 JP JP2007545917A patent/JP2008523130A/ja active Pending
- 2005-12-12 CN CN2005800416868A patent/CN101072773B/zh not_active Expired - Fee Related
- 2005-12-12 PE PE2005001434A patent/PE20060736A1/es not_active Application Discontinuation
- 2005-12-12 WO PCT/EP2005/013297 patent/WO2006063763A1/en active Application Filing
- 2005-12-12 BR BRPI0518607-2A patent/BRPI0518607A2/pt not_active IP Right Cessation
- 2005-12-12 US US11/720,786 patent/US20100087432A1/en not_active Abandoned
- 2005-12-12 PT PT05815747T patent/PT1828172E/pt unknown
- 2005-12-12 ES ES05815747T patent/ES2335519T3/es active Active
- 2005-12-12 AU AU2005315881A patent/AU2005315881C1/en not_active Ceased
- 2005-12-12 DE DE602005017935T patent/DE602005017935D1/de active Active
- 2005-12-12 EP EP05815747A patent/EP1828172B1/en not_active Not-in-force
- 2005-12-12 PL PL05815747T patent/PL1828172T3/pl unknown
- 2005-12-12 MX MX2007007098A patent/MX2007007098A/es active IP Right Grant
- 2005-12-13 TW TW094143970A patent/TW200635921A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
BRPI0518607A2 (pt) | 2008-11-25 |
DE602005017935D1 (de) | 2010-01-07 |
EP1828172B1 (en) | 2009-11-25 |
CN101072773A (zh) | 2007-11-14 |
ES2335519T3 (es) | 2010-03-29 |
PL1828172T3 (pl) | 2010-05-31 |
GT200500360A (es) | 2006-08-07 |
GB0427381D0 (en) | 2005-01-19 |
RU2007126761A (ru) | 2009-01-27 |
EP1828172A1 (en) | 2007-09-05 |
TW200635921A (en) | 2006-10-16 |
WO2006063763A1 (en) | 2006-06-22 |
AU2005315881B2 (en) | 2009-09-24 |
AU2005315881A1 (en) | 2006-06-22 |
PT1828172E (pt) | 2010-02-17 |
CA2587934A1 (en) | 2006-06-22 |
ATE449772T1 (de) | 2009-12-15 |
JP2008523130A (ja) | 2008-07-03 |
AU2005315881C1 (en) | 2010-03-11 |
PE20060736A1 (es) | 2006-09-08 |
KR20070087605A (ko) | 2007-08-28 |
CN101072773B (zh) | 2011-01-19 |
US20100087432A1 (en) | 2010-04-08 |
MX2007007098A (es) | 2007-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR052266A1 (es) | Derivados de pirroles, su preparacion, y su uso como compuestos farmaceuticos | |
AR081058A1 (es) | Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer. | |
AR106942A2 (es) | Compuestos de isoindolina y composiciones farmacéuticas de los mismos | |
AR111425A2 (es) | MODULADORES SELECTIVOS DE RECEPTORES DE ANDRÓGENOS (SARMs) Y COMPOSICIONES FARMACÉUTICAS QUE LOS COMPRENDEN | |
LTPA2016032I1 (lt) | Hipoglikeminių agentų skyrimo būdai | |
CY1119049T1 (el) | Υποκατεστημενα πυρρολιδινο-2-καρβοξαμιδια | |
DOP2011000264A (es) | Derivados de aminotetralina, composiciones farmaceuticas que los contienen y sus usos en terapia | |
SV2010003767A (es) | Compuestos pirazolicos 436 | |
EA201200049A1 (ru) | 1,3-дизамещенные производные имидазолидин-2-она в качестве ингибиторов cyp 17 | |
AR063015A1 (es) | Derivados de quinazolinona 5-sustituida y composiciones que los comprenden y metodos para utilizarlos en el tratamiento del cancer | |
BRPI0507312A (pt) | derivados de quinolina para uso como inibidores micobacterianos | |
ATE539079T1 (de) | Imidazochinoxalinverbindungen als immunmodulatoren | |
EA200870193A1 (ru) | Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение | |
AR072906A1 (es) | Nucleosidos modificados utiles como antivirales | |
UY32691A (es) | Compuestos de 1h-imidazo-[4,5-c]-quinolinona | |
NO20080129L (no) | Fremgangsmate for fremstilling av dihydrokinazoliner | |
AR083268A1 (es) | Conjugado de naloxol-peg cristalino | |
AR071120A1 (es) | Derivados de diosmetina, su procedimiento de preparacion, las composiciones farmaceuticas que los contienen y su uso en el tratamiento de las enfermedades venosas cronicas. | |
AR054000A1 (es) | Compuesto de n-(fenilpropil)-sulfonamida, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento, producto de combinacion que comprende dicho compuesto y metodo para prepararlo | |
CR10206A (es) | Acidos4-fenil-tiazol-5-carboxilicos amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1 | |
AR078278A1 (es) | Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro. | |
DOP2011000335A (es) | Combinacion antitumoral que comprende ave8062 y sorafenib | |
AR063027A1 (es) | Derivados de sulfonamida | |
ITMI20041151A1 (it) | Nanoparticelle lipidiche come agenti veicolanti per acidi nucleici procedimento per la loro preparazione e loro uso | |
UY30356A1 (es) | Derivados de 3-halo-n-(2.(4-fluorofenil)-4-oxobutil)-n-metil-5-(trifluorometil)benzamida y composiciones de los mismos. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |